- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07940361
Ultrashort Echo Time (UTE) MRI for Applicator Reconstruction in Gynaecologic Cancer Brachytherapy (UTE)
The goal of this clinical study is to learn whether an ultrashort echo time (UTE) MRI scan can show the position of brachytherapy applicators and needles more accurately than standard MRI scans in adults with gynaecologic cancer (cervical, endometrial, or vaginal cancer) who are receiving MRI-guided internal radiotherapy (brachytherapy).
The main questions it aims to answer are:
- Does UTE MRI locate the applicator and needle tips more accurately than standard T2-weighted (T2W) and proton-density-weighted (PDW) MRI, when compared with CT?
- Does UTE MRI show a clearer contrast between the applicator and the surrounding tissue?
Researchers will compare applicator positions reconstructed from UTE, T2W, and PDW MRI with CT taken on the same day as the reference standard. They will also check whether differences in applicator reconstruction change the planned radiation dose, and whether image features (radiomics) from UTE MRI before treatment and before brachytherapy help predict cancer recurrence.
Participants will:
- Receive their usual standard brachytherapy treatment, which is not changed by this study
- Have one additional MRI sequence (UTE, about 8 minutes) added to their standard MRI and CT scans at each brachytherapy planning session, with the applicator in place
- Have an additional UTE sequence added to their routine MRI before treatment and before brachytherapy
- Be followed during routine clinical visits for disease outcomes
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Background MRI-guided adaptive brachytherapy is the standard of care for locally advanced gynaecologic cancer. T2-weighted MRI is the reference sequence for target delineation, but applicator and interstitial needle reconstruction on T2W MRI is limited by low contrast between the uterus and titanium applicators and by susceptibility artefacts, with reported geometric distortion of up to about 7 mm. Proton-density-weighted MRI (TE about 5.5 ms) improves tandem visualisation but remains limited for interstitial needles and residual blooming artefact. Ultrashort echo time (UTE) MRI (TE below 1 ms) captures signal from very short-T2 structures and is expected to reduce susceptibility artefact around metallic and plastic applicators. No prospective study has compared UTE with PDW and T2W MRI for intracavitary/interstitial applicator reconstruction in gynaecologic brachytherapy.
Hypothesis UTE MRI will localise the applicator tip more accurately than PDW and T2W MRI, with a mean tip-localisation error of no more than 1.2 mm relative to same-day CT, and will provide a higher uterus-to-applicator contrast-to-noise ratio (CNR), with about 8 minutes of additional scan time.
Study design Single-centre, prospective, single-group study at the Division of Radiation Oncology, Faculty of Medicine Siriraj Hospital, Mahidol University. Standard treatment is not altered.
Phase 1 - Phantom validation An MR- and CT-compatible phantom holding tandem-ring, tandem-ovoid, vaginal cylinder, intracavitary/interstitial applicators and interstitial needles in multiple orientations will be imaged with CT and MRI (T1W, T2W, UTE) without moving the applicator. Image quality (SNR, CNR, apparent applicator diameter, tip/channel visibility, geometric distortion, susceptibility artefact) will be assessed. Source dwell positions will be verified by autoradiography using an Ir-192 source. Dosimetric impact will be assessed with AAPM TG-43 calculations on simulated targets and organs at risk.
Phase 2 - Clinical validation After applicator insertion, at each brachytherapy planning session participants will undergo standard CT and MRI (T2W, PDW) with an additional 3D UTE sequence (1.5 mm isotropic, TE below 0.1 ms) on a Philips 1.5T Ingenia Ambition X system, with the applicator in situ and minimal time between scans. Three experienced medical physicists will independently reconstruct applicators on each image set, blinded and in randomised order. Applicator-based rigid registration between CT and MRI with a registration quality score will be used to separate reconstruction error from applicator displacement; only registrations meeting predefined acceptance criteria will be analysed. Comparison plans (CT reference, T2W, UTE) will use identical contours, dwell positions, and dwell times so that dose differences reflect reconstruction alone.
Phase 3 - Radiomics An additional UTE sequence will be acquired with routine T2W and DWI at pre-treatment and pre-brachytherapy time points. Radiomic features will be extracted from tumour ROIs (MIM software) and evaluated for prognostic value for locoregional and distant recurrence, in addition to existing T2W- and DWI-based models, using Kaplan-Meier and Cox proportional hazards analyses.
Sample size and analysis Target enrolment is 50 adult patients (about 150 imaging sessions). Assuming tip error of 1.2 +/- 1.0 mm for UTE versus 1.8 +/- 1.2 mm for PDW, a paired t-test with two-sided alpha 0.05 and 80% power (d = 0.46) was used. Agreement with CT will be assessed by Bland-Altman analysis; sequences will be compared with repeated-measures ANOVA or linear mixed-effects models; inter- and intra-observer agreement by ICC; and dosimetric parameters (CTV-HR D90/D98, OAR D2cc and others) with correction for multiple comparisons.
Support Philips (Thailand) Ltd. provides research equipment support without funding. The company has no role in study design, participant selection, data collection, analysis, interpretation, writing, or the decision to publish.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tissana Prasartseree, M.D.
- Numéro de téléphone: 66625246101
- E-mail: tissana.p@gmail.com
Sauvegarde des contacts de l'étude
- Nom: Pittaya Dankulchai, M.D.
- Numéro de téléphone: 66966233606
- E-mail: pittaya.dan@mahidol.ac.th
Lieux d'étude
-
-
Bangkok
-
Bangkok, Bangkok, Thaïlande, 10700
- Faculty of Medicine Siriraj Hospital, Mahidol University
-
Contact:
- Tissana Prasartseree, M.D.
- Numéro de téléphone: 66625246101
- E-mail: tissana.p@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Gynaecologic malignancy (cervix/endometrium/vagina) requiring BT with intracavitary or hybrid IC/IS applicator
- Locally advanced cervical, endometrial, or vaginal cancer undergoing MRI-guided BT
- Age ≥ 18 years
- ECOG 0-2
- Written informed consent
Exclusion Criteria:
- MRI contraindication (incompatible implant, severe claustrophobia)
- non-MRI-compatible applicator required
- inability to tolerate ~8 mins additional scan time
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: UTE MRI
Gynaecologic malignancy (cervix/endometrium/vagina) requiring BT with intracavitary or hybrid IC/IS applicator. At every planning/fraction session: T2W, PDW, 3D UTE (1.5 mm isotropic) and same day CT (reference), all with applicator in situ on a Philips 1.5T system. An additional UTE sequence will be acquired alongside the standard T2W and DWI sequences at pre-treatment and pre-brachytherapy time points. |
Ultrashort Echo Time sequence (EFO 033), TE < 0.1 ms, investigational Philips sequence, on Philips 1.5T MR Systems Ingenia Ambition X release 5.7. 3D UTE (1.5 mm isotropic) acquired at every planning/fraction session with applicator in situ, in addition to T2W and PDW (~8 mins additional scan time).
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Applicator/needle tip-localisation error
Délai: Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Applicator/needle tip-localisation error of UTE among the T2W, PDW MRI sequences, using same day CT as reference (geometric gold standard). Reported in millimetres. |
Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
|
Contrast-to-noise ratio (CNR)
Délai: Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Contrast-to-noise ratio (CNR) between uterus and applicator of UTE among the T2W and PDW MRI sequences. |
Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage dose difference of brachytherapy plan from UTE among the T2W, PDW MRI sequences and CT
Délai: Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Dosimetric agreement of brachytherapy plan from UTE among the T2W, PDW MRI sequences and CT, including CTV-HR D90, CTV-HR D98, CTV-HR V100, CTV-IR D90, CTV-IR D98, and Bladder, Rectum, Sigmoid Colon and Small Bowel D0.1cc, D1cc and D2cc. |
Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
|
Radiomics prognostic value for locoregional and distant recurrence
Délai: Pre-treatment and pre-brachytherapy timepoints, followed up to 3 years
|
Radiomics with UTE at pre-treatment and pre-brachytherapy timepoints for locoregional and distant recurrent prognostic value in addition to the existing T2W- and DWI-based model (Kaplan-Meier survival analysis and Cox regression analysis). Reported as Hazard Ratio (HR) with 95% CI. |
Pre-treatment and pre-brachytherapy timepoints, followed up to 3 years
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies utérines
- Maladies génitales, femme
- Tumeurs génitales, femme
- Maladies du col de l'utérus
- Tumeurs utérines
- Maladies vaginales
- Tumeurs du col de l'utérus
- Tumeurs de l'endomètre
- Tumeurs vaginales
- Techniques et procédures de diagnostic
- Diagnostic
- Tomographie
- Imagerie diagnostique
- Imagerie par résonance magnétique
Autres numéros d'identification d'étude
- Si 784/2569(IRB1)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .